FDA Debars Another Man from Drug Industry for Unauthorized Import and Sale of Omeprazole
The Food and Drug Administration issued an order debarring David Freeman for five years from providing services to any person that has an approved or pending drug product application, in connection with his 2010 conviction for introducing and delivering into…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
commerce a misbranded drug. Along with his accomplice Ashley Brandon Foyle, Freeman imported omeprazole from Muhi Trading Corporation, and his company Omega Biotech had repackaged and sold the drug. Neither Freeman, Omega, or Muhi Trading were registered to manufacture, prepare, propagate, compound, or process drugs, FDA said. The agency already published an order debarring Foyle on May 1 (see 13043018).